CTKB (Cytek Biosciences) Interest Coverage : 0 (At Loss) (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cytek Biosciences's Operating Income for the three months ended in Sep. 2024 was $-4.2 Mil. Cytek Biosciences's Interest Expense for the three months ended in Sep. 2024 was $-0.1 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Cytek Biosciences's Interest Coverage or its related term are showing as below:

CTKB's Interest Coverage is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 19.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cytek Biosciences Interest Coverage Historical Data

The historical data trend for Cytek Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cytek Biosciences Interest Coverage Chart

Cytek Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

2,763.00

41.02

5.26

Cytek Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cytek Biosciences's Interest Coverage

For the Medical Devices subindustry, Cytek Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytek Biosciences's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Interest Coverage falls into.

Cytek Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cytek Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Cytek Biosciences's Interest Expense was $-2.1 Mil. Its Operating Income was $-27.8 Mil. And its Long-Term Debt & Capital Lease Obligation was $11.1 Mil.

Cytek Biosciences did not have earnings to cover the interest expense.

Cytek Biosciences's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Cytek Biosciences's Interest Expense was $-0.1 Mil. Its Operating Income was $-4.2 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.0 Mil.

Cytek Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Cytek Biosciences (NAS:CTKB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Cytek Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytek Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

47215 Lakeview Boulevard, Fremont, CA, USA, 94538

Website

https://www.cytekbio.com

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Executives

Ming Yan	director, officer: Chief Technology Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Patrick Jeanmonod	officer: Chief Financial Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang	director, officer: President and CEO	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque	officer: SVP, Global Sales and Services	47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams	officer: Chief Operating Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison	director
Deborah J Neff	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron	director	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng	director	SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116